Pharmacokinetic parameters were estimated by non-compartmental analysis using WinNonLin Enterprise Version 5.2 or later (Pharsight Corporation, Mountain View, CA, USA) or SAS® Version 9.2 (SAS Institute Inc., Cary, NC, USA). The plasma parameters assessed for AZD5069 were maximum (peak) drug concentration (Cmax), time to reach maximum concentration (tmax), area under plasma concentration–time curve from zero to infinity after a single dose (AUC), AUC from zero to time 12 h (AUC0–12), AUC from zero to time 24 h (AUC0–24), AUC during a dose interval at steady state (AUCss), terminal elimination rate constant (λz), terminal half-life (t½), apparent oral plasma clearance (CL/F), renal clearance (CLR) and apparent oral volume of distribution during terminal phase (Vz/F).
Winnonlin enterprise version 5
Manufactured by Pharsight
Sourced in United States
WinNonlin Enterprise Version 5.2 is a software application developed by Pharsight for the analysis of pharmacokinetic and pharmacodynamic data. It provides a comprehensive set of tools for the modeling and simulation of drug concentration and response data.
Automatically generated - may contain errors
Lab products found in correlation
4 protocols using winnonlin enterprise version 5
1
Pharmacokinetic Analysis of AZD5069
2
Dexlansoprazole Pharmacokinetics Across Doses
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Pharmacokinetic analyses included all patients with at least one estimable dexlansoprazole pharmacokinetic parameter on day 7. Dexlansoprazole pharmacokinetic parameters were determined from the plasma concentration–time profiles for all dose groups on day 7, using actual, rather than scheduled, sampling times. Pharmacokinetic parameters were derived using noncompartmental methods, with WinNonlin® Enterprise Version 5.2 (Pharsight Corp, St Louis, MO, USA). Pharmacokinetic parameters were summarized using descriptive statistics for each dose group. In addition, pharmacokinetic parameters were summarized by patient body weight and age groups.
Analysis of covariance (ANCOVA) models, with baseline weight as a continuous factor and dose group as a fixed factor, were used for tmax and the natural logarithm of dose-normalized Cmax and AUC. Pairwise comparisons between dose groups were conducted. Dose proportionality was assessed using the ratios of dose-normalized Cmax and AUC central values.
Analysis of covariance (ANCOVA) models, with baseline weight as a continuous factor and dose group as a fixed factor, were used for tmax and the natural logarithm of dose-normalized Cmax and AUC. Pairwise comparisons between dose groups were conducted. Dose proportionality was assessed using the ratios of dose-normalized Cmax and AUC central values.
3
Pharmacokinetics of MIV-711 in Plasma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Blood samples were collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 h post-dose and processed into plasma for the measurement of concentrations of MIV-711. The PK analysis was conducted using WinNonlin Enterprise Version 5.2 (Pharsight Corporation, Mountain View, CA, USA).
4
Pharmacokinetic Analysis of PRT062607
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Pharmacokinetic calculations based on PRT062607 plasma concentrations were performed by Covance Laboratories (Princeton, New Jersey) using noncompartmental analysis in WinNonlin Enterprise Version 5.2 (Pharsight Corporation, Mountain View, California). Individual plasma concentration data from each subject and the exact time points for blood sampling were used throughout the analysis. Pharmacokinetic parameters calculated from plasma PRT062607 concentrations included, but were not limited to, Cmax, tmax, AUC0‐24, λz, and t1/2. Dose‐normalized values for Cmax and AUC0‐24 were calculated and captured as Cmax/D and AUC/D, respectively. Accumulation ratio based on Cmax was calculated as Cmax,day 10/Cmax,day 1 and for AUC as AUC0‐24,day 10/AUC0‐24,day 1. Peak‐to‐trough ratio was computed as the ratio of Cmax on day 10 to the 24‐hour concentration postdose on day 10. Fluctuation on day 10 was calculated as (Cmax ‐ Cmin)/Cavg where Cmin is the minimum concentration and Cavg is the average concentration. From urine data, cumulative amount excreted from time 0 to 24 hours postdose (Ae0‐24) and cumulative fraction of dose excreted unchanged in the urine from time 0 to 24 hours postdose (fe0‐24) were also determined. Renal clearance (CLr) was calculated as the ratio of Ae0‐24 to AUC0‐24 on day 10.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!